Summit Therapeutics (SMMT) Operating Leases (2018 - 2026)

Summit Therapeutics (SMMT) has reported Operating Leases for 9 consecutive years, with $16.8 million the latest figure, recorded in Q2 2026.

• Quarterly Operating Leases rose 591.33% year-over-year to $16.8 million in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $16.8 million (up 591.33% YoY) and the FY2025 annual result came in at $17.5 million, up 406.86% from the prior year.
• Operating Leases was little changed at $16.8 million in Q2 2026 per SMMT's latest filing, from $16.9 million in the prior quarter.
• Over the last five years, Operating Leases for SMMT reached as high as $17.5 million in Q4 2025 and fell as low as $1.3 million in Q2 2022.
• A 5-year average of $5.6 million and a median of $3.4 million in 2023 frame the typical range for Operating Leases.
• Annual changes were most pronounced in 2025 — Operating Leases slumped 51.47% — and 2026, when it jumped 591.33%.
• Year by year, Operating Leases stood at $2.8 million in 2022, then increased by 19.07% to $3.3 million in 2023, then climbed by 4.95% to $3.5 million in 2024, then jumped by 406.86% to $17.5 million in 2025, then decreased by 3.82% to $16.8 million in 2026.
• According to Business Quant data, Operating Leases over the past three periods registered $16.8 million, $16.9 million, and $17.5 million for Q2 2026, Q1 2026, and Q4 2025 respectively.